WLF Directly Targets FDAMA Rather Than FDA Off-Label Reg In April 29 Brief
This article was originally published in The Gray Sheet
The Washington Legal Foundation's April 29 brief filed in the case of WLF v. Henney on off-label dissemination provisions of the FDA Modernization Act focuses primarily on the law rather than the agency's regulation implementing the statute.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.